Factors ID'd That Affect Medical Decision-Making in Hidradenitis Suppurativa
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 17, 2024 -- Factors that affect medical decision-making among patients with hidradenitis suppurativa (HS) include suffering threshold, perceptions of treatment risk, treatment fatigue, understanding of the disease, and sources of information, according to a study published online Jan. 10 in JAMA Dermatology.
Nicole Salame, M.D., from the Emory University School of Medicine in Atlanta, and colleagues examined factors that affect the medical decision-making process for patients with HS. Open-ended semistructured interviews were conducted with 21 English-speaking adults with HS recruited from two dermatology clinics. On a 0- to 10-point numeric rating scale, participants had an average seven-day pain score of 1 or higher.
The researchers found that 96 percent of the participants had Hurley stage II or III disease and 71 percent had a history of adalimumab use. Factors affecting participants' decisions to initiate new treatments for HS included suffering threshold, perceptions of treatment risk, treatment fatigue, disease understanding, and sources of information (dermatologists, the internet, advertisements, and friends and loved ones).
"By addressing misconceptions about perceived risks, identifying gaps in disease knowledge, and emphasizing the importance of early treatment to prevent scarring and disease progression, dermatologists may empower patients with HS to make informed and meaningful treatment decisions and to try new therapies," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Clinical Markers Improve With IV Ertapenem for Hidradenitis Suppurativa
WEDNESDAY, Feb. 21, 2024 -- Treatment of hidradenitis suppurativa (HS) with intravenous ertapenem is associated with improvement in clinical and inflammatory markers, according to...
Barbers Can Partner With Dermatologists to Augment Pseudofolliculitis Barbae Care
MONDAY, Dec. 11, 2023 -- An educational intervention targeted at barbers substantially increases knowledge regarding the causes, prevention, and treatment of pseudofolliculitis...
Sexual, Gender Minorities With Chronic Skin Diseases More Likely to Face Barriers to Care
TUESDAY, Oct. 3, 2023 -- Sexual and gender-minority (SGM) patients with chronic inflammatory skin diseases (CISDs) are more likely to experience cost and noncost barriers to care...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.